½ÃÀ庸°í¼­
»óǰÄÚµå
1585597

¹ÙÀÌ¿À¹ðÅ© ½ÃÀå : ±¸¼º¿ä¼Ò, »ùÇà À¯Çü, ¿ëµµº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Biobanks Market by Component (Consumables, Equipment, Services), Sample Type (Biological Fluids, Blood Products, Cell Lines), Application - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 187 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¹ÙÀÌ¿À¹ðÅ© ½ÃÀåÀº 2023³â¿¡ 678¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 757¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 11.80%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1,481¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹ÙÀÌ¿À¹ðÅ©´Â Ç÷¾×, ¼¼Æ÷, Á¶Á÷, DNA µî »ý¹°ÇÐÀû »ùÇÃÀ» ¼öÁýÇϰí ÀúÀåÇÏ´Â Áß¿äÇÑ ÀúÀå°í·Î, ÁÖ·Î ¿¬±¸¿Í ÀÇÇÐ ¹ßÀüÀ» À§ÇØ »ç¿ëµË´Ï´Ù. ¹ÙÀÌ¿À¹ðÅ©ÀÇ Çʿ伺Àº °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í À¯Àüü ¿¬±¸¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ °­Á¶µÇ°í ÀÖÀ¸¸ç, Áúº´ ÁøÇà, ¾à¹° °³¹ß, ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¿¬±¸¿¡ Áß¿äÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇϱ⠶§¹®ÀÔ´Ï´Ù. ¹ÙÀÌ¿À¹ðÅ©ÀÇ ¿ëµµ´Â Çмú¿¬±¸±â°ü, Á¦¾àȸ»ç, º´¿ø µî ´Ù¾çÇϸç, ÃÖÁ¾ ¿ëµµ´Â °³ÀÎ ¸ÂÃãÇü ÀÇ·á, ¾Ï ¿¬±¸, Àç»ýÀÇ·á·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¹ðÅ© ½ÃÀåÀº À¯Àüü ±â¼úÀÇ ¹ßÀü, ¹ÙÀÌ¿À¹ðÅ· ÇÁ·ÎÁ§Æ®¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÚ±Ý Áö¿ø, ¹ÙÀÌ¿À Á¦¾à»çµéÀÇ ½Å¾à°³¹ß ÀÌ´Ï¼ÅÆ¼ºê¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡ µîÀÇ ¿äÀο¡ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÃÖ±Ù ÀáÀçÀûÀÎ ºñÁî´Ï½º ±âȸ´Â µ¥ÀÌÅÍ °ü¸® ¹× º¸¾ÈÀ» À§ÇÑ ÀΰøÁö´É°ú ºí·ÏüÀΰú °°Àº µðÁöÅÐ ±â¼úÀÇ ÅëÇÕ¿¡ ÀÖ½À´Ï´Ù. µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã¿¡ ´ëÇÑ À±¸®Àû ¹®Á¦, ¹ÙÀÌ¿À¹ðÅ© °ü¸®¿Í °ü·ÃµÈ ³ôÀº ºñ¿ë, ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â º¹ÀâÇÑ ±ÔÁ¦ µîÀÌ °úÁ¦·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Ã·áÀÇ º¸°ü ǰÁú°ú ¹ÙÀÌ¿À¹ðÅ© ½Ã¼³ °£ Ç¥ÁØÈ­¿¡ ´ëÇÑ ¿ì·Áµµ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¸¦ ±Øº¹Çϱâ À§Çؼ­´Â ³Ãµ¿º¸°ü ±â¼úÀ» °³¼±Çϰí, ½Ã·á ¼öÁý ¹× º¸°üÀÇ Ç¥ÁØÈ­ ÇÁ·ÎÅäÄÝÀ» °³¹ßÇÏ¿© °íǰÁúÀÇ ÀçÇö °¡´ÉÇÑ ½Ã·á µ¥ÀÌÅ͸¦ È®º¸ÇÏ´Â µ¥¿¡ ±â¼ú Çõ½ÅÀ» ÁýÁßÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ KEYWORD °£ÀÇ °øµ¿ ³×Æ®¿öÅ©´Â ÀÚ¿ø°ú Áö½ÄÀÇ °øÀ¯¸¦ ÃËÁøÇÏ°í ¿¬±¸ °³¹ßÀÇ ÁøÀüÀ» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀåÀº ³ôÀº °æÀï°ú ºü¸¥ ±â¼ú ÁøÈ­°¡ Ư¡À̸ç, ÃÖ÷´Ü ¿ª·®À» À¯ÁöÇϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ°¡ ÇÊ¿äÇÕ´Ï´Ù. Àü¹ÝÀûÀ¸·Î ¹ÙÀÌ¿À¹ðÅ© ½ÃÀåÀº ±â¼ú ÅëÇÕ°ú °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó Å« ¼ºÀå ÀáÀç·ÂÀ» °¡Áö°í ÀÖÀ¸¸ç, Àü·«Àû Á¦ÈÞ¿Í µ¥ÀÌÅÍ º¸¾È °­È­°¡ ¼º°øÀÇ ¿­¼è¸¦ Áã°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 678¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 757¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 1,481¾ï ´Þ·¯
CAGR(%) 11.80%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ¹ÙÀÌ¿À¹ðÅ© ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¹ÙÀÌ¿À¹ðÅ© ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«Àû ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡
    • ¹ÙÀÌ¿À¹ðÅ©¿¡ ´ëÇÑ ÀÎ½Ä Á¦°í
    • ´ë±Ô¸ð ³ë·É Àα¸ÃþÀÇ Á¸Àç¿Í ÇÔ²² Àα¸ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¹ÙÀÌ¿À ¹ðÅ· °ü·Ã À±¸®Àû, ¹ýÀû À̽´
  • ½ÃÀå ±âȸ
    • °¢±¹ÀÇ À¯Àüü ¿¬±¸ Ȱµ¿ Ȱ¼ºÈ­
    • À¯Àüü °Ë»ç ¹× Áٱ⼼Æ÷ Ä¡·á¿¡ ´ëÇÑ ÀϹÝÀεéÀÇ ÀÎ½Ä Á¦°í
  • ½ÃÀå °úÁ¦
    • ¹ÙÀÌ¿À¹ðÅ©ÀÇ Àå±âÀû Áö¼Ó°¡´É¼º

Portre's Five Forces: ¹ÙÀÌ¿À¹ðÅ© ½ÃÀå °ø·«À» À§ÇÑ Àü·«Àû µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ¹ÙÀÌ¿À¹ðÅ© ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â µ¥ Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ¸ð»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¹ÙÀÌ¿À¹ðÅ© ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¹ÙÀÌ¿À¹ðÅ© ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ¹ÙÀÌ¿À¹ðÅ© ½ÃÀåÀÇ °æÀï»óȲ ÆÄ¾Ç

¹ÙÀÌ¿À¹ðÅ© ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ º¥´õÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ¹ÙÀÌ¿À¹ðÅ© ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¹ÙÀÌ¿À¹ðÅ© ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿À¹ðÅ© ½ÃÀå¿¡¼­ÀÇ ¼º°ø Àü·« ºÐ¼® ¹× Ãßõ ¹ÙÀÌ¿À¹ðÅ© ½ÃÀå¿¡¼­ÀÇ ¼º°ø °æ·Î¸¦ ±×¸®´Ù.

¹ÙÀÌ¿À¹ðÅ© ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ¹ÙÀÌ¿À¹ðÅ© ½ÃÀå : ÄÄÆ÷³ÍÆ®º°

  • ¼Ò¸ðǰ
  • Àåºñ
  • ¼­ºñ½º
  • ¼ÒÇÁÆ®¿þ¾î

Á¦7Àå ¹ÙÀÌ¿À¹ðÅ© ½ÃÀå : »ùÇà À¯Çüº°

  • ü¾×
  • Ç÷¾× Á¦Ç°
  • ¼¼Æ÷ÁÖ
  • Àΰ£ Á¶Á÷
  • ÇÙ»ê

Á¦8Àå ¹ÙÀÌ¿À¹ðÅ© ½ÃÀå : ¿ëµµº°

  • ÀÓ»ó ¿¬±¸
  • »ý¸í°úÇÐ ¿¬±¸
  • Àç»ýÀÇ·á

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ¹ÙÀÌ¿À¹ðÅ© ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¹ÙÀÌ¿À¹ðÅ© ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¹ÙÀÌ¿À¹ðÅ© ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Acorn Biolabs, Inc.
  • Artizan Biosciences, Inc.
  • Bay Biosciences LLC
  • Beckman Coulter, Inc. by Danaher Corporation
  • Becton, Dickinson and Company
  • BioLife Solutions Inc.
  • LVL Technologies GmbH & Co. KG
  • Merck KGaA
  • ProteoGenex, Inc.
  • Provia Laboratories, LLC
  • Shanghai Zhangjiang Biobank
  • Taylor-Wharton
  • Tecan Trading AG
  • Thermo Fisher Scientific Inc.
  • UK Biobank Limited
LSH 24.11.13

The Biobanks Market was valued at USD 67.81 billion in 2023, expected to reach USD 75.75 billion in 2024, and is projected to grow at a CAGR of 11.80%, to USD 148.10 billion by 2030.

Biobanks are crucial repositories that collect and store biological samples such as blood, cells, tissues, and DNA, predominantly for research and medical advancements. Their necessity is underscored by the increasing demand for personalized medicine and genomic research, as they provide critical data for studies on disease progression, drug development, and biomarker discovery. The application of biobanks spans across academic research institutions, pharmaceutical companies, and hospital settings, with a growing end-use scope in personalized healthcare, cancer research, and regenerative medicine. The market for biobanks is influenced by factors such as advances in genomic technologies, government funding for biobanking projects, and growing investments by biopharma companies in drug discovery initiatives. The latest potential opportunities lie in the integration of digital technologies like artificial intelligence and blockchain for data management and security-allowing more efficient sample tracking and usage, which can significantly enhance research outputs. Challenges include ethical concerns over data privacy, high costs associated with biobank management, and regulatory complexities which can impede market growth. There are also concerns over sample storage quality and standardization across biobanking facilities. To overcome these challenges, innovation can be directed towards improving cryopreservation techniques and developing standardized protocols for sample collection and storage to ensure high-quality and reproducible sample data. Additionally, collaborative networks among biobanks can facilitate the sharing of resources and knowledge, fostering advancements in research and development. The market is characterized by high competition and rapid technological evolution, necessitating continuous investment in R&D to maintain cutting-edge capabilities. Overall, the biobank market holds significant potential for growth driven by technological integration and a growing emphasis on personalized medicine, with strategic collaborations and enhanced data security being pivotal for success.

KEY MARKET STATISTICS
Base Year [2023] USD 67.81 billion
Estimated Year [2024] USD 75.75 billion
Forecast Year [2030] USD 148.10 billion
CAGR (%) 11.80%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biobanks Market

The Biobanks Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in incidence of chronic disease
    • Rising awareness about biobanks
    • Increasing population coupled with presence of a large geriatric population base
  • Market Restraints
    • Ethical and legal issues related to biobanking
  • Market Opportunities
    • Growing genomic research activities in economies
    • Increasing public awareness about genomic testing and stem cell therapies
  • Market Challenges
    • Long-Term Sustainability of Biobanks

Porter's Five Forces: A Strategic Tool for Navigating the Biobanks Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biobanks Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biobanks Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biobanks Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biobanks Market

A detailed market share analysis in the Biobanks Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biobanks Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biobanks Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biobanks Market

A strategic analysis of the Biobanks Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biobanks Market, highlighting leading vendors and their innovative profiles. These include Acorn Biolabs, Inc., Artizan Biosciences, Inc., Bay Biosciences LLC, Beckman Coulter, Inc. by Danaher Corporation, Becton, Dickinson and Company, BioLife Solutions Inc., LVL Technologies GmbH & Co. KG, Merck KGaA, ProteoGenex, Inc., Provia Laboratories, LLC, Shanghai Zhangjiang Biobank, Taylor-Wharton, Tecan Trading AG, Thermo Fisher Scientific Inc., and UK Biobank Limited.

Market Segmentation & Coverage

This research report categorizes the Biobanks Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Component, market is studied across Consumables, Equipment, Services, and Software.
  • Based on Sample Type, market is studied across Biological Fluids, Blood Products, Cell Lines, Human Tissues, and Nucleic Acids.
  • Based on Application, market is studied across Clinical Research, Life Science Research, and Regenerative Medicine.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in incidence of chronic disease
      • 5.1.1.2. Rising awareness about biobanks
      • 5.1.1.3. Increasing population coupled with presence of a large geriatric population base
    • 5.1.2. Restraints
      • 5.1.2.1. Ethical and legal issues related to biobanking
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing genomic research activities in economies
      • 5.1.3.2. Increasing public awareness about genomic testing and stem cell therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Long-Term Sustainability of Biobanks
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biobanks Market, by Component

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Equipment
  • 6.4. Services
  • 6.5. Software

7. Biobanks Market, by Sample Type

  • 7.1. Introduction
  • 7.2. Biological Fluids
  • 7.3. Blood Products
  • 7.4. Cell Lines
  • 7.5. Human Tissues
  • 7.6. Nucleic Acids

8. Biobanks Market, by Application

  • 8.1. Introduction
  • 8.2. Clinical Research
  • 8.3. Life Science Research
  • 8.4. Regenerative Medicine

9. Americas Biobanks Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Biobanks Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Biobanks Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Acorn Biolabs, Inc.
  • 2. Artizan Biosciences, Inc.
  • 3. Bay Biosciences LLC
  • 4. Beckman Coulter, Inc. by Danaher Corporation
  • 5. Becton, Dickinson and Company
  • 6. BioLife Solutions Inc.
  • 7. LVL Technologies GmbH & Co. KG
  • 8. Merck KGaA
  • 9. ProteoGenex, Inc.
  • 10. Provia Laboratories, LLC
  • 11. Shanghai Zhangjiang Biobank
  • 12. Taylor-Wharton
  • 13. Tecan Trading AG
  • 14. Thermo Fisher Scientific Inc.
  • 15. UK Biobank Limited
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦